Why did the European Commission grant approval to AbbVie (NYSE:ABBV)?

The European Commission granted approval to AbbVie (NYSE:ABBV) because its drug MAVIRET demonstrated high efficacy in treating acute hepatitis C virus infections. The authorization expands options for adult and pediatric patients aged three years and older with compensated liver disease.

What is the treatment layout and regimen length for the AbbVie (NYSE:ABBV) drug?

The treatment layout for the AbbVie (NYSE:ABBV) drug MAVIRET consists of a short eight-week regimen. This timeline applies to both adult and pediatric patients who meet the clinical eligibility criteria.

What clinical trial details and safety outcomes were observed by AbbVie (NYSE:ABBV)?

The approval for AbbVie (NYSE:ABBV) was supported by data from a Phase 3 study that demonstrated high clinical efficacy. The observed adverse events were primarily mild to moderate, including fatigue, diarrhea, headache, and asthenia.

What is the medical pipeline scope of this AbbVie (NYSE:ABBV) therapy?

The therapeutic pipeline scope expands because MAVIRET by AbbVie (NYSE:ABBV) is now the only approved treatment in the European Union for both acute and chronic hepatitis C virus infections. It covers patients with compensated liver disease, with or without cirrhosis.

What geographic market impact does this clearance have for AbbVie (NYSE:ABBV)?

This clearance allows AbbVie (NYSE:ABBV) to market its specialized hepatitis C treatment across all European Union member states. The approval broadens commercial reach within the continental pediatric and adult antiviral therapy markets.

Image for illustrative purposes only. Not a real photo.

AbbVie receives European Commission approval for MAVIRET in acute hepatitis C

Written by Liezl GambePublished Jun 23, 2026, 9:08 AM

The European Commission approved AbbVie's MAVIRET to treat acute hepatitis C virus in adults and children aged three and older.
Following the regulatory announcement, the company's stock price closed up at $230.01.
The regulatory clearance advances the long-term corporate strategy of expanding global pediatric and antiviral product portfolios.

AbbVie (NYSE:ABBV) said the European Commission has granted approval for its oral antiviral MAVIRET (glecaprevir/pibrentasvir) to treat acute hepatitis C virus (HCV) infection in adults and pediatric patients aged 3 years and older with compensated liver disease, with or without cirrhosis.

With this approval, MAVIRET becomes the only treatment in the European Union approved for both acute and chronic HCV infection.

The approval was supported by data from a Phase 3 study evaluating an eight-week regimen, which demonstrated high efficacy rates along with a safety profile consisting mainly of mild to moderate adverse events, including fatigue, diarrhea, headache, and asthenia.

The company stated that this development aligns with its strategy to scale antiviral treatments across multiple age brackets.